title: High Levels of Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Acute Stroke: An Age- and Sex-Matched Cross-Sectional Study.
abstract: OBJECTIVE
  Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is known to be a key molecule in the pathogenesis of atherosclerosis. Although high levels of serum soluble LOX-1 (sLOX-1) were demonstrated in patients with acute coronary syndrome, there are no reports about acute stroke patients. The aim of the present study was to evaluate the levels of sLOX-1 in acute stroke patients according to different stroke subtypes.
  
  
  METHODS
  We enrolled a total of 377 patients with a stroke (men/women: 251/126; age: 40-79 years), 250 with ischemic stroke and 127 with intracerebral hemorrhage (ICH). Patients were admitted to our hospital within 3 days after the onset of stroke. As controls, we randomly selected age- and sex-matched subjects without a past history of cardiovascular disease according to stroke subtype from the community-based cohort of the Suita study. Serum LOX-1 levels were compared between stroke patients and healthy controls according to stroke subtype.
  
  
  RESULTS
  Median values of serum sLOX-1 in stroke patients were significantly higher than those in controls (526 vs. 486 ng/L in ischemic stroke and 720 vs. 513 ng/L in ICH, respectively). Among subtypes of ischemic stroke, median sLOX-1 levels in atherothrombotic brain infarction (641 ng/L) only were significantly higher than those in controls (496 ng/L). Ischemic stroke [odds ratio (OR), 3.80; 95% confidence interval (CI), 1.86-7.74] and ICH (OR, 5.97; 95% CI, 2.13-16.77) were independently associated with high levels of sLOX-1 by multivariate logistic regression analysis.
  
  
  CONCLUSIONS
  Higher levels of sLOX-1 were observed in patients with acute stoke than in controls. High levels of sLOX-1 can be useful as biomarker for acute stroke.
authors.affiliation: Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
authors.forename: Chiaki
authors.initials: C
authors.lastname: Yokota
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Sawamura
authors.forename: Makoto
authors.initials: M
authors.lastname: Watanabe
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kokubo
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Fujita
authors.forename: Akemi
authors.initials: A
authors.lastname: Kakino
authors.forename: Michikazu
authors.initials: M
authors.lastname: Nakai
authors.forename: Kazunori
authors.initials: K
authors.lastname: Toyoda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Kazuo
authors.initials: K
authors.lastname: Minematsu
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D050197:Atherosclerosis / Q000097:blood / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D051127:Scavenger Receptors, Class E / Q000097:blood*; D012737:Sex Factors; D020521:Stroke / Q000097:blood / Q000175:diagnosis*
chemical_list: D015415:Biomarkers; C495137:OLR1 protein, human; D051127:Scavenger Receptors, Class E